Petros Grivas, MD, on the significance of a perioperative regimen for cisplatin-ineligible MIBC

Data from the KEYNOTE-905 trial (NCT03924895) showed that perioperative enfortumab vedotin plus pembrolizumab significantly improved event-free survival (0.40), overall survival (0.50), and pathological complete response rate (57% vs 9%) compared with surgery alone in patients with cisplatin-ineligible MIBC.¹

In a recent interview with Urology Times®, Petros Grivas, MD, PhD, described the results as “paradigm shifting,” given that previously, there have been no established neoadjuvant options for cisplatin-ineligible patients. He also noted that that upcoming results from the phase 3 KEYNOTE-B15/EV-304 trial in cisplatin-eligible patients will further inform this space.

Grivas is a professor at the University of Washington and a genitourinary oncologist at the Fred Hutchinson Cancer Center in Seattle, Washington.

REFERENCE

1. Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. Presented at: 2025 European Society for Medical Oncology Congress. October 17-21, 2025. Berlin, Germany. Abstract LBA2. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/LBA2.html.pdf